Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 127 of 5804
-
Can a new drug help when standard treatment fails for polycythemia vera?
Disease control Not yet recruitingResearchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, al…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New immunotherapy targets rare cancers by harnessing the Body's immune system
Disease control Not yet recruitingThis phase II trial studies how well brenetafusp (IMC-F106C) works in treating patients with preferentially expressed antigen of melanoma (PRAME) positive synovial sarcoma and myxoid/round cell liposarcoma that has spread from where it first started (primary site) to other places…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for SMA babies: boosting gene therapy with a Follow-Up drug
Disease control Not yet recruitingIn this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have already been treated with onasemnogene abeparvovec (OA) after being diagnosed with…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to stall endometrial cancer
Disease control Not yet recruitingThe purpose of this study is to see how well GSK5733584 in combination with standard treatment of choice works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared to current standard of care. The study will also assess whether drug c…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a single drug calm lupus kidney disease without a cocktail of meds?
Disease control Not yet recruitingLupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity. International 2024 guidelines recommend immunosuppressive therapy (MMF, cyclophosphamide, calcineurin inhibitors, rituximab, azathioprine) in patien…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New trial combines HIV PrEP and STI prevention in one package for young men
Disease control Not yet recruitingIndividual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
Phase: PHASE3 • Sponsor: HIV Prevention Trials Network • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
Disease control Not yet recruitingThis phase I trial tests the safety, side effects, and best dose of total body irradiation (TBI) in combination with standard of care lymphodepletion with cyclophosphamide and fludarabine before tisagenlecleucel (Tisa-cel) and how well the combination works in patients with large…
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingTherapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become…
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Two-Drug combo aims to shrink vulvar tumors before surgery
Disease control Not yet recruitingCOLOMBE is a multicenter, single arm, phase 1/2 trial designed to evaluate the safety and efficacy of imiquimod cream with IV low dose nivolumab in primary resectable vulvar squamous cell carcinoma patients prior to surgery, leveraging the preoperative "window of opportunity" per…
Phase: PHASE1, PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New daily pill aims to tame stubborn seizures in tuberous sclerosis
Disease control Not yet recruitingThis Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC). Approximately 42 participants will be randomized in a 5:1 ratio to…
Phase: PHASE2 • Sponsor: Aeovian Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common diabetes drug stop diabetes after kidney transplant?
Prevention Not yet recruitingThe goal of this clinical trial is to find out whether 12 months of treatment with the SGLT2 inhibitor Forxiga® (dapagliflozin 10 mg once daily), compared with placebo, can reduce the risk of developing post-transplant diabetes in kidney transplant recipients who do not have diab…
Phase: PHASE2 • Sponsor: Odense University Hospital • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
Spinal implant and Mind-Controlled rehab may restore arm movement after stroke
Disease control Not yet recruitingThis clinical study aims to evaluate the efficacy and safety of spinal cord stimulation combined with non-invasive motor imagery brain-computer interface rehabilitation training in patients with upper limb motor dysfunction after chronic stroke. The study includes an experimental…
Phase: NA • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Gut bacteria transplant may supercharge liver cancer immunotherapy
Disease control Not yet recruitingHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited therapeutic options. Despite the advances in immunotherapy, a substantial proportion of patients fail to respon…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation
Disease control Not yet recruitingObese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to sustain. Tirzepatide, a once-weekly GIP/GLP-1 dual recept…
Phase: PHASE4 • Sponsor: Yunlong Wang • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a One-Two drug punch beat back Hard-to-Treat myeloma?
Disease control Not yet recruitingThis is a Phase 1, open-label dose escalation study evaluating the safety and clinical efficacy of Talquetamab in combination with Belantamab mafodotin for a time-limited interval followed by Belantamab mafodotin and Pomalidomide maintenance. The study will enroll subjects with …
Phase: PHASE1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a new drug cut seizure days in juvenile myoclonic epilepsy?
Disease control Not yet recruitingThis study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
Phase: PHASE2, PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
AI-Designed TB treatment aims for 99.5% cure rate
Disease control Not yet recruitingTuberculosis (TB) kills 1.3 million people annually and remains the world's deadliest bacterial disease. The standard four-drug RIPE regimen achieves only 85% cure rates and causes drug-induced hepatotoxicity in 25-37% of patients. Hydroxychloroquine (HCQ), an FDA-approved antima…
Phase: PHASE2 • Sponsor: Ministry of Health, Saudi Arabia • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a higher dose of rifampicin cut TB treatment time for kids?
⭐️ CURE ⭐️ Not yet recruitingCurrent tuberculosis (TB) treatment is effective (works well), but it takes a long time to cure TB. This study will evaluate if TB treatment with a higher dose of rifampicin, one of the TB medicines, and shorter TB treatment duration is as effective and safe as the standard, TB t…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New Bladder-Sparing combo aims to avoid surgery in cancer patients
Disease control Not yet recruitingThis is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Selective cell removal may tame stem cell Transplant's dangerous side effect
Disease control Not yet recruitingThis phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant diseases requiring hematopoietic cell transplantation. Giving chemotherapy and total-body irradiation before a donor peripher…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC